================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
SCHEDULE 14D-1
Tender Offer Statement Pursuant to
Section 14(d)(1) of the Securities Exchange Act of 1934
AMENDMENT NO. 3
CoCensys, Inc.
(Name of Subject Company)
Purdue Acquisition Corporation
Purdue Pharma L.P.
(Bidders)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
191263201
(CUSIP Number of Class of Securities)
Howard R. Udell, Esq.
Purdue Acquisition Corporation
c/o Purdue Pharma L.P.
100 Connecticut Avenue
Norwalk, Connecticut 06850-3590
(203) 853-0123
(Name, Address and Telephone Number of Persons Authorized to
Receive Notices and Communications on Behalf of Bidder)
____________________
Copy To:
Stuart D. Baker, Esq.
Chadbourne & Parke LLP
30 Rockefeller Plaza
New York, New York 10112
(212) 408-5100
================================================================================
<PAGE>
This Amendment No. 3 to the Tender Offer Statement on Schedule 14D-1 (this
"Amendment") relates to a tender offer by Purdue Acquisition Corporation, a
Delaware corporation ("Offeror"), and an indirect wholly owned subsidiary of
Purdue Pharma L.P., a Delaware limited partnership ("Parent"), to purchase all
outstanding shares of Common Stock, par value $0.001 per share (the "Common
Stock"), including the associated rights to purchase Series A Junior
Participating Preferred Stock issued under the Rights Agreement (as defined in
the Offer to Purchase) (the "Rights" and together with the Common Stock, the
"Shares") of CoCensys, Inc., a Delaware corporation (the "Company"), at a
purchase price of $1.16 per Share, net to the seller in cash (subject to any
applicable withholding of taxes), without interest, upon the terms and subject
to the conditions set forth in the Offeror's Offer to Purchase, dated August 12,
1999, as amended (the "Offer to Purchase"), and in the related Letter of
Transmittal (which together constitute the "Offer").
Unless otherwise indicated, all capitalized terms used but not defined
herein shall have the respective meanings assigned to them in the Offer to
Purchase.
Item 1. Security and Subject Company
Item 1 of the Schedule 14D-1 is hereby amended and supplemented by adding
the following text thereto:
On September 23, 1999, the Company and Warner-Lambert Company
("Warner-Lambert") agreed to amend the W-L Note to provide Warner-Lambert the
option to convert the W-L Note into an amount of Shares equal to the principal
amount of the W-L Note plus accrued intrerest as of September 23, 1999 divided
by the Offer Price. Warner-Lambert has also agreed to tender such Shares in the
Offer contigent on the Offeror accepting for payment all Shares validly tendered
prior to the Expiration Date.
2
<PAGE>
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: September 23, 1999
PURDUE PHARMA L.P., by its
general partner, PURDUE PHARMA INC.
By: /S/ Stuart D. Baker
--------------------------------
Name: Stuart D. Baker
Title: Vice President
PURDUE ACQUISITION CORPORATION
By: /S/ Stuart D. Baker
--------------------------------
Name: Stuart D. Baker
Title: Vice President
3
